AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $240,306 | -3.2% | 19,762 | 0.0% | 0.09% | +4.8% |
| Q2 2023 | $248,211 | +13.3% | 19,762 | 0.0% | 0.08% | +3.7% |
| Q1 2023 | $219,161 | -5.9% | 19,762 | +3.6% | 0.08% | -12.0% |
| Q4 2022 | $232,991 | +17.1% | 19,082 | 0.0% | 0.09% | +4.5% |
| Q3 2022 | $199,000 | -2.9% | 19,082 | 0.0% | 0.09% | +3.5% |
| Q2 2022 | $205,000 | +13.3% | 19,082 | 0.0% | 0.08% | +39.3% |
| Q1 2022 | $181,000 | -26.4% | 19,082 | -10.4% | 0.06% | -17.6% |
| Q4 2021 | $246,000 | +21.2% | 21,304 | 0.0% | 0.07% | +15.6% |
| Q3 2021 | $203,000 | -1.0% | 21,304 | 0.0% | 0.06% | +1.6% |
| Q2 2021 | $205,000 | -2.4% | 21,304 | 0.0% | 0.06% | -4.5% |
| Q1 2021 | $210,000 | -6.7% | 21,304 | +118.8% | 0.07% | -9.6% |
| Q4 2020 | $225,000 | -18.2% | 9,737 | -50.0% | 0.07% | -29.8% |
| Q3 2020 | $275,000 | -5.2% | 19,479 | +1.5% | 0.10% | -11.1% |
| Q2 2020 | $290,000 | +48.0% | 19,198 | -9.6% | 0.12% | +21.9% |
| Q1 2020 | $196,000 | -51.2% | 21,242 | -48.5% | 0.10% | -39.6% |
| Q4 2019 | $402,000 | – | 41,242 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |